Blog

Transcreener Assay Used to Help Discover CPS1 Inhibitor

CPS1 Inhibitor Researcher at the Bench
Researchers look to discover a CPS1 inhibitor with an eye on cancer – Without properly functioning carbamoyl-phosphate synthetase I (CPS1), large amounts of highly toxic ammonia is able to accumulate in the body contributing to neurological conditions.2  Increased levels of the enzyme have been found in some cancers including lung adenocarcinoma (LADC).1 When overexpressed, CPS1
Read more
No Comments

New Transcreener CD73 Assay for Discovery of Therapeutics to Enhance Tumor Immunity

cGAS Inhibitors Grant
The new Transcreener CD73 Assay measures adenosine production by CD73 in a mix-and-read format with a far-red fluorescence polarization readout. The assay will accelerate efforts to discover selective CD73 antagonists for cancer immunotherapy by enabling high throughput screening, structure-driven hit-to-lead, and mechanistic studies with the purified enzyme. Madison, WI – April 27th, 2020 – Researchers
Read more
No Comments

Recorded Webinar – Transcreener® CD73 Assay: Leveraging Nucleotide Detection to Measure Adenosine

Webinar Graphic
CD73 is a plasma membrane-bound ectonucleotidase that hydrolyzes AMP into adenosine, contributing to immunosuppression in the tumor microenvironment; it is being pursued as a promising immuno-oncology drug target. In this webinar we will present the steps involved in development of the Transcreener CD73 assay. Transcreener is a biochemical HTS assay platform based on homogenous immunodetection
Read more
No Comments

FUT7, Inflammation, and Fucosyltransferase Assays

FUT7 Fucosyltransferase Assays and Chronic Inflammation
Inflammation is a necessary step involved in the immune response, allowing our bodies to fight and eliminate disease, allergies, and injuries. The inflammatory response recruits several mediators to aid in the destruction of whatever pathogen caused the response in the first place. Cells such as leucocytes, eosinophils, and neutrophils get recruited to the site in
Read more
No Comments

Transcreener Assay Used to Evaluate PI3K Inhibitors

PI3K Inhibitors for Cancer Research
PI3K Inhibitors and Cancer – Although cancer is widespread, determining the culprit, as well as individual treatment, is challenging. A variety of cancer types exist with a multitude of contributors. Being the most common human genetic disease, a whole host of genes are involved. Some contribute to curbing cancer (tumor suppressor genes), while oncogenes promote
Read more
No Comments

Fluorescence Polarization Assays for Drug Discovery

FP Assays
Fluorescence polarization assays (FP assays) are used in a variety of ways.  From uncovering molecules in solution, to monitoring drug levels in clinical settings, and are enabling in drug discovery. These binding assays have been used to gain knowledge of molecular interactions, enzymatic activity, and nucleic acid hybridization. Moreover, scientists use FP to study small
Read more
No Comments

Transcreener ADP Assay Used to Discover RIPK1 Inhibitors

RIPK1 Inhibitors Inflammatory disease treatment
Genentech discovers novel RIPK1 inhibitors – Like other serine/threonine protein kinases, receptor-interacting serine/threonine-protein kinase 1 (RIPK1) plays a role in several signaling pathways that keep us living healthy, functioning lives. RIPK1 is one of those enzymes’ that wears a variety of hats depending on what function needs attention. It contributes to cell death as well
Read more
No Comments

TR-FRET Assays In Drug Discovery

TR-FRET Assays
Förster resonance energy transfer (FRET) technology and TR-FRET assays are used in laboratories globally for a variety of applications ranging from disease detection, to drug discovery, to monitoring genetic differences between individuals and populations. The brilliance of this technology is due to the sensitivity provided by the spectral overlap and the proximity of the acceptor
Read more
No Comments

SLAS 2020 – Discover HTS Assays for Drug Discovery

SLAS 2020 Conference
  BellBrook Labs will exhibit and present posters at the upcoming SLAS 2020 conference in San Diego, CA. At the conference BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, targeting ENPP1, studying CD73, screening for kinase inhibitors, using Transcreener for a cGAS drug discovery program, and more!
Read more
No Comments

ST6GAL1 Drug Discovery to Combat Cancer

ST6GAL1 Drug Discovery
The number of cancer hallmarks has increased as the knowledge and understanding of the disease progress. As many of us already know, the basic characteristic is a mutation that causes uncontrollable cell growth causing a tumor. Cancer is truly a multi-step development that enables cells to survive, proliferate and metastasize. Other hallmarks of the disease
Read more
No Comments

Recent Posts

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

TOP